Evidence map›Paper›PMID 30473701›Full record

ArticleFrontiers in immunology2018

IFNAR2 Is Required for Anti-influenza Immunity and Alters Susceptibility to Post-influenza Bacterial Superinfections.

Kelly M Shepardson, Kyle Larson, Laura L Johns, Kayla Stanek, Hanbyul Cho, Julia Wellham, Haley Henderson, Agnieszka Rynda-Apple

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Exposing the Two Contrasting Faces of STAT2 in Inflammation.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kelly M ShepardsonRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Kyle LarsonRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Laura L JohnsRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Kayla StanekRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Hanbyul ChoRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Julia WellhamRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Haley HendersonRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Agnieszka Rynda-AppleRynda-Apple Laboratory, Department of Microbiology and Immunology, Montana State University, Bozeman, MT, United States.
Montana State University · US

Funding

KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium TCP Transfer to UC DavisUM1OD023221 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KC KENT LLOYD · 2016 to 2026
$45.7M
Pilot Grants ProgramP30GM110732 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2014 to 2018
$5.4M
Development of novel, safe and efficacious Coxiella burnetii vaccineR21AI119772 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI JUTILA, MARK A, RYNDA-APPLE, AGNIESZKA · 2015 to 2016
$396k
NIAID NIH HHS R21 AI119772NIGMS NIH HHS P30 GM110732NIH HHS UM1 OD023221
6 · The paper itself

Abstract

Influenza virus infections particularly when followed by bacterial superinfections (BSI) result in significant morbidities and mortalities especially during influenza pandemics. Type I interferons (IFNs) regulate both anti-influenza immunity and host susceptibility to subsequent BSIs. These type I IFNs consisting of, among others, 14 IFN-α's and a single IFN-β, are recognized by and signal through the heterodimeric type I IFN receptor (IFNAR) comprised of IFNAR1 and IFNAR2. However, the individual receptor subunits can bind IFN-β or IFN-α's independently of each other and induce distinct signaling. The role of type I IFN signaling in regulating host susceptibility to both viral infections and BSI has been only examined with respect to IFNAR1 deficiency. Here, we demonstrate that despite some redundancies, IFNAR1 and IFNAR2 have distinct roles in regulating both anti-influenza A virus (IAV) immunity and in shaping host susceptibility to subsequent BSI caused by

Indexed as

AnimalsDisease SusceptibilityFemaleInfluenza A virusMaleMiceMice, Inbred C57BLOrthomyxoviridae InfectionsReceptor, Interferon alpha-betaStaphylococcal InfectionsStaphylococcus aureusSuperinfectionVaccinationIfnar2 protein, mouseReceptor, Interferon alpha-betaIFNAR1IFNAR2InfluenzaStaphylococcus aureussuperinfection

Identifiers

PMID30473701
PMCPMC6237881
OpenAlexW2899642211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.